A5071753660- Cervical Cancer and HPV Research
- Endometrial and Cervical Cancer Treatments
- Hepatitis B Virus Studies
- Genital Health and Disease
- Global Cancer Incidence and Screening
- Women's cancer prevention and management
- Colorectal and Anal Carcinomas
- Uterine Myomas and Treatments
- Child Nutrition and Water Access
- Vaccine Coverage and Hesitancy
- Endometriosis Research and Treatment
- Ovarian cancer diagnosis and treatment
- Banana Cultivation and Research
- Effects of Environmental Stressors on Livestock
- Growth and nutrition in plants
- Molecular Biology Techniques and Applications
- Reproductive tract infections research
- Herpesvirus Infections and Treatments
- Urinary and Genital Oncology Studies
- COVID-19 Impact on Reproduction
- Genetic and phenotypic traits in livestock
- Global Maternal and Child Health
- Rural Development and Agriculture
- Parasitic Infections and Diagnostics
- Healthcare during COVID-19 Pandemic
Universidade Estadual de Campinas (UNICAMP)
2016-2025
Universidade Nove de Julho
2024
Hospital de Clínicas da Unicamp
2014-2016
St. Luke's-Roosevelt Hospital Center
2015
Icahn School of Medicine at Mount Sinai
2015
Universidade Federal de Juiz de Fora
2004-2014
Universidade Federal do Rio Grande do Sul
2005-2011
DDL Diagnostic Laboratory
2011
GlaxoSmithKline (Brazil)
2011
Administração Regional de Saúde de Lisboa e Vale do Tejo
2006
HPV-023 (NCT00518336; ClinicalTrial.gov) is a long-term follow-up of an initial double-blind, randomized (1:1), placebo-controlled study (HPV-001, NCT00689741) evaluating the efficacy against human papillomavirus (HPV)-16/18 infection and associated cyto-histopathological abnormalities, persistence immunogenicity, safety HPV-16/18 AS04-adjuvanted vaccine. Among women, aged 15–25 years, enrolled in HPV-001 who participated HPV-007 (NCT00120848), subset 437 women from five Brazilian centers...
This double-blind, multicenter, randomized, placebo-controlled study was conducted to assess the efficacy of a bivalent human papillomavirus (HPV)-16/18 L1 virus-like particle vaccine in preventing cervical infection with HPV-16/18. The participants were recruited among healthy women aged 15 25 years from 32 healthcare facilities Brazil, Canada, and United States. A total 1113 enrolled study. Enrollees had 6 or fewer lifetime sexual partners, no history abnormality, negative for high-risk...
The control arm of PATRICIA (PApilloma TRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk progression from cervical HPV infection intraepithelial neoplasia (CIN) or clearance infection, and associated determinants.Women aged 15-25 years were enrolled. A 6-month persistent (6MPI) defined as detection same type at two consecutive evaluations over 6 months ≥2 type-specific negative samples taken intervals approximately following a positive sample. primary...
Prophylactic human papillomavirus (HPV) vaccines are now available and vaccination programs being widely implemented, targeting adolescent girls prior to sexual debut. Since the risk of HPV exposure persists throughout a woman's life, duration protection provided by is critical overall vaccine effectiveness. We report long-term efficacy immunogenicity HPV-16/18 AS04-adjuvanted (Cervarix®) up 8.4 y after first dose. In an initial placebo-controlled study performed in US, Canada Brazil, women...
In the Phase III PATRICIA study (NCT00122681), human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) was highly efficacious against HPV-16/18 infections and precancerous lesions in women deoxyribose nucleic acid (DNA) negative seronegative at baseline. We present further data on efficacy (VE) total vaccinated cohort including who may have been exposed to infection before vaccination. with no evidence of current or previous (DNA seronegative), VE...
ABSTRACT We report final event-driven analysis data on the immunogenicity and efficacy of human papillomavirus 16 18 ((HPV-16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from PApilloma TRIal against Cancer In Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one dose (vaccine, n = 9,319; control, 9,325) months 0, 1, and/or 6. TVC-naive 5,822; 5,819) had no evidence high-risk HPV infection baseline, approximating...
We evaluated the efficacy of human papillomavirus (HPV)−16/18 AS04‐adjuvanted vaccine in preventing HPV‐related disease after surgery for cervical lesions a post‐hoc analysis PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681). Healthy women aged 15–25 years were randomized (1:1) to receive or control at months 0, 1 and 6 followed 4 years. Women enrolled regardless their baseline HPV DNA status, HPV‐16/18 serostatus, cytology, but excluded if they had previous planned...
Background. Public Health England has reported a decrease of up to 20.8% in new diagnoses external genital warts (GWs) among women aged <19 years since the national vaccination program with human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began 2008. A post hoc analysis phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed ascertain whether protection low-risk HPV types apparent. Methods. Vaccine efficacy (VE) at 48 months assessed...
We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681) on association between behavioral risk factors and HPV infection cervical abnormalities.Women completed questionnaires at baseline. Prevalence of abnormalities (detected by cytological or histological procedures) with were analyzed univariate stepwise multivariable logistic regressions.16782 women questionnaires. Among 16748 for infection, 4059 (24.2%) infected any type. 16757...
The present study assesses the implementation and impact after 2 years of a school-based human papillomavirus (HPV) vaccination program in Brazilian city. A prospective assessing program, offering quadrivalent HPV vaccine two annual doses to girls boys aged from 9 10 old. was started city Indaiatuba, state São Paulo, Brazil, 2018, had authorization National Immunization Program. number first applied coverage 2018 calculated compared year 2017. There were described events that have influenced...
We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment PATRICIA (Papilloma Trial Against Cancer Young Adults; NCT00122681).Using Poisson regression, we compared associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) the control arm (DNA negative baseline for corresponding [HPV-16: n = 8193; HPV-18: 8463]).High titers naturally acquired HPV-16 antibodies and/or...
Current HPV vaccines do not protect against all oncogenic types. Following vaccination, type replacement may occur, especially if different types competitively interact during natural infection. Because of their common route transmission, it is difficult to assess interactions in observational studies. Our aim was evaluate the setting vaccine randomized controlled trials (RCTs).Data were pooled from Costa Rica Vaccine Trial (CVT; NCT00128661) and PATRICIA trial (NCT001226810)-two...
The objective of the present study was to characterize Giardia duodenalis infection among children living in sub-standard settlement areas municipality Juiz de Fora, Minas Gerais State, Brazil. cross-sectional epidemiological included 590 from 1 5 years age. Data were collected one child per selected family through home interviews with parent or guardian and parasitological examination stool samples. Thirty-one putative risk factors concerning structure, socioeconomic status, environmental...
O artigo teve como objetivo desenvolver um estudo do impacto sobre a saúde pública das deficiências saneamento básico no Brasil período de 2001 2009. Os óbitos resultantes doenças relacionadas ao inadequado corresponderam, em média, 13.449 mortes por ano, ou seja, cerca 1,31% total. A média anual casos notificação compulsória devido foi 466.351 casos, com uma despesa R$ 30.428.324,92 consultas médicas nesse período. Foi identificada também 758.750 internações hospitalares básico, total...
Objectives Persistence of human papillomaviruses (HPVs) is necessary for cervical carcinogenesis. We evaluated incidence and duration type-specific HPV infections the influence age number sexual partners. Methods Data were obtained from 553 women (15–25 years), who seronegative DNA-negative high-risk (HR-HPV) types enrolled in placebo arm a randomised trial HPV-16/18 vaccine ( NCT00689741 /NCT00120848). They followed 6.3 years. Cervicovaginal samples self-collected at 3-month intervals up to...
More information is needed about time between sexual initiation and human papillomavirus (HPV) infection development of cervical precancer.The objectives were to investigate the first activity detection HPV or intraepithelial neoplasia (CIN), associated factors in women from double-blind, multinational, 4-year PATRICIA trial. enroled aged 15-25 years with no more than 6 lifetime partners. Women randomized 1:1 HPV-16/18 AS04-adjuvanted vaccine control, but only control arm who began...
The benefits of chemoradiotherapy (CRT) for cervical cancer compared with radiation (RT) alone seem to diminish in later-stage disease. However, these modalities have not been directly disease-free interval (DFI) and overall survival (OS) women stage IIIB cancer.We conducted a randomized controlled clinical trial comparing DFI OS 147 squamous who received either cisplatin plus RT or (72 patients the CRT group 75 RT-only group).The had significantly better (hazard ratio [HR], 0.52; 95% CI,...
Objective To report a modelling study using local health care costs and epidemiological inputs from population-based program to access the cost-effectiveness of adopting hrHPV test. Methods A analysis based on microsimulation dynamic Markov model. Data were data setting literature review. The was Indaiatuba, Brazil, that has adopted test in place cytology since 2017. After calibrating model, one million women simulated hypothetical cohorts. Three strategies tested: aged 25 64 every three...